Профилактика венозных тромбоэмболических осложнений у «трудных» пациентов

1. Кириенко А.И., Панченко Е.П., Андрияшкин В.В. Венозный тромбоз в практике терапевта и хирурга. Планида, 2012.
2. Rutherford RB (editor). Vascular surgery, ELSEVIER Saunders 2005, ISBN 0-7216-0299-1.
3. Caprini J, Wentworth D. Venous thrombosis prophylaxis. Venous and Lymphatic Diseases edited by N. Labropoulos and G. Stansby, Taylor&Francis 2006, ISBN-13: 978-0-8247-2923-3; 173–204.
4. Geerts W, Berqvist D, Pineo G et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl.): 381S–453.
5. Kearon C, Kahn S, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl.): 354S–545.
6. Blossom D, Kallen A, Patel P et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674–84.
7. Kishimoto Т, Viswanathan K, Ganguly T et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457–67.
8. Явелов И.С. Препараты низкомолекулярного гепарина: основные свойства и возможности создания аналогов. Клинич. фармакология и терапия. 2010; 19: 56–63.
9. Gainor C, Vanscoy G, Niccolai C, Rihn T. Pharmacologic and liability considerations of therapeutic interchange with low-molecular-weight heparins. Hospital Pharmacy 2003; 38 (7): 652–8.
10. Gray E, Mulloy B. Biosimilar low molecular heparin products. J Thromb Haemost 2009; 7: 1218–21.
11. Planes A. Review of bemiparin sodium-a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother 2003; 4 (9): 1551–61.
12. Falkon L, Saenz-Campos D, Antonijoan R et al. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb Res 1995; 78: 77–86.
13. Falkon L, Bayes M, Frontera G et al. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers- a dose-finding study within the therapeutical range. Thromb Haemost 1997; 77: 133–6.
14. Collignon F, Frydman A, Caplain et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin, nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630–40.
15. Eriksson BI, Soderberg K, Widlund L et al. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398–401.
16. Breddin HK. Reviparin sodium – a new low molecular weight heparin. Expert Opin Pharmacother 2002; 3: 173–82.
17. Santamaria A, Juarez S, Reche A et al. Low-molecular weight heparin, Bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: THE ESFERA study. Clinical Practice 2006; 60: 518–25.
18. Borrell M, Antonijoan RM, Ortin R et al. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb Haemost 2001; 86 (Suppl.): CD3578 (Abstract).
19. Depasse F, Gonzalez De Suso M, Lagoutte I et al. Comparative study of the pharmacokinetic profiles of two LMWH – Bemiparin (3,500 IU anti-Xa) and Tinzaparin (4,500 IU anti-Xa) – administered subcutaneously to healthy male volunteers. Thromb Res 2003; 109: 109–17.
20. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost 2000; 83: 523–9.
21. Navarro-Quilis A, Castellet E, Rocha E et al. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J Thromb Haemost 2003; 1: 425–32.
22. Planes A, Vochelle M, Fagola M, Bellaud M. Comparison of two low molecular weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis 1998; 9: 499–505.
23. Planes A, Vochelle N, Gonzalez De Suso MJ, Claracq JP. Profilaxis antitrombotica poscirurgia ortopedica con bemiparina, heparina de bajo peso molecular de segundageneracion. Rev Anestesiol Reanim 2001; 48: 258–63.
24. Rico S, Antonijoan RM, Martıґnez-Colomer J et al. Pharmacokinetics and safety of bemiparin after multipleprophylactic and single therapeutic doses in young and elderly healthy volunteers-no need for dose adjustment. J Thromb Haemost 2009; 7 (Suppl. 2): Abstract PP-WE-415.
25. Martır E, Mateo J, Santamarıґa A et al. Eficacia y seguridadde Bemiparina (Hibor) administrada a largo plazo enpacientes croґnic amenteanti coagulados quehansufrido hemorragia gastrointestinal grave recurrente. Haematoloґgica 2007; 92 (Suppl. 2): Abstract C-164.
26. Rodriquez-Manas L, Gomez-Huelgas R, Veiga-Fernandez F et al. Thromboprophylaxis with the Low-Molecular-Weight Heparin Bemiparin Sodium in Elderly Medical Patients in Usual Clinical Practice. The ANCIANOS study. Clin Drug Investig 2010; 30 (5): 337–45.
27. Rico S, Antonijoan RM, Martıґnez-Colomer J et al. Pharmacokinetics and safety of bemiparin after multipleprophylactic and single therapeutic doses in young and elderly healthy volunteers-no need for dose adjustment. J ThrombHaemost 2009; 7 (Suppl. 2): Abstract PP-WE-415.
28. Boj JF. New Frontiers with Bemiparin. Drugs 2010; 70 (Suppl. 2): 43–7.
29. Heit JA, Kobbervig CE, James AH et al. Trends in the incidence of venous thromboembolism during pregnancy orpostpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10): 697–706.
30. Gibson PS, Powrie R. Anticoagulants and pregnancy: when are they safe? Cleve Clin J Med 2009; 76 (2): 113–27.
31. Royal College of Obstetricians and Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: Acute management. 2007 [cited 17 Feb 2010]. Availablefrom: http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT28ThromboembolicDisease2007.pdf.
32. Bates SM, Greer IA, Hirsh J et al. Use of antithromboticagents during pregnancy: the Seventh ACCP Conferenceon Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 3): 627S–44S.
33. Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81 (5): 668–72.
34. Pettila V, Leinonen P, Markkola A et al. Postpartum bonemineral density in women treated for thromboprophylaxiswith unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87 (2): 182–6.
35. Santamarıґa A, Vila J, Marco A et al. Clinical management using low-molecular-weight heparin (LMWH) in pregnantwomen with thrombophilia, thromboembolic disease (DVT) or thrombophilia-related maternoplacental syndrome: experiencein one center. Published in: J Thromb Haemost 2007; 5 (Suppl. 2): P-W-587.
36. Rey E, Rivard GE. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet 2000; 71 (1): 19–24.
37. Casele HL, Laifer SA, Woelkers DA et al. Changes in thepharmacokinetics of the low-molecular-weight heparinenoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181 (5 Pt 1): 1113–7.
38. Bates SM, Greer IA, Pabinger I et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-BasedClinical Practice Guidelines (8th edn). Chest 2008; 133 (Suppl. 6): 844S–86S.
39. Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83 (5): 1251–7.
40. Payne JH. Aspects of anticoagulation in children. Br J Haematol 2010; 150 (3): 259–77.
41. Fraga Rodrıґguez GM, Parody Porras R, Ginovart Galiana G et al. Renal venous thrombosis in a neonate carrying theG20210A mutation of prothrombin. An Pediatr (Barc) 2005; 62: 480–1.
42. Miras-Parra F, Navascues-Martinez E, Gomes-Outes A et al. Utilisation and Safety of Bemiparin, a Low-Molecular-Weight Heparin, in Medical Patients. A prospective, Uncontrolled Cohort Study. Clin Drug Invest 2005; 25 (7): 463–72.

В.Ю.Богачев, О.В.Голованова, А.Н.Кузнецов

ГБОУ ВПО РНИМУ им. Н.И.Пирогова, Минздрава РФ, Москва